Net Income (Loss) Attributable to Parent of THC Therapeutics, Inc. from 31 Jul 2010 to 31 Jul 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
THC Therapeutics, Inc. quarterly and annual Net Income (Loss) Attributable to Parent in USD history and change rate from 31 Jul 2010 to 31 Jul 2024.
  • THC Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 31 Jul 2024 was $281,724, a 755% decline year-over-year.
  • THC Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 31 Jul 2024 was $811,562, a 110% decline year-over-year.
  • THC Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was $811,562, a 110% decline from 2023.
  • THC Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was $387,036, a 75% increase from 2022.
  • THC Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $1,518,929, a 19% increase from 2021.
Source SEC data
View on sec.gov
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

THC Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2024 $811,562 $281,724 -$248,783 -755% 01 May 2024 31 Jul 2024 10-K 27 Feb 2026 2024 FY
Q1 2024 $562,779 $104,622 +$10,267 +11% 01 Feb 2024 30 Apr 2024 10-Q 13 Nov 2024 2024 Q3
Q4 2023 $573,046 $571,975 -$2,257,827 -134% 01 Nov 2023 31 Jan 2024 10-Q 13 Nov 2024 2024 Q3
Q3 2023 $1,684,781 $62,485 +$2,071,817 +97% 01 Aug 2023 31 Oct 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $387,036 $32,941 -$385,187 -109% 01 May 2023 31 Jul 2023 10-K 27 Feb 2026 2024 FY
Q1 2023 $1,849 $94,355 +$726,633 01 Feb 2023 30 Apr 2023 10-Q 13 Nov 2024 2024 Q3
Q4 2022 $728,482 $1,685,852 +$2,438,312 01 Nov 2022 31 Jan 2023 10-Q 13 Nov 2024 2024 Q3
Q3 2022 $3,166,794 $2,134,302 -$1,647,865 -339% 01 Aug 2022 31 Oct 2022 10-Q 13 Nov 2024 2024 Q3
Q2 2022 $1,518,929 $352,246 +$1,437,036 01 May 2022 31 Jul 2022 10-K 26 Feb 2024 2023 FY
Q1 2022 $2,955,965 $632,278 -$281,498 -80% 01 Feb 2022 30 Apr 2022 10-Q 09 Jan 2024 2023 Q3
Q4 2021 $2,674,467 $752,460 -$392,635 -109% 01 Nov 2021 31 Jan 2022 10-Q 09 Jan 2024 2023 Q3
Q3 2021 $2,281,832 $486,437 -$396,387 -440% 01 Aug 2021 31 Oct 2021 10-Q 09 Jan 2024 2023 Q3
Q2 2021 $1,885,445 $1,084,790 01 May 2021 31 Jul 2021 10-K 25 Nov 2022 2022 FY
Q1 2021 $350,780 +$909,283 +72% 01 Feb 2021 30 Apr 2021 10-Q 16 Jun 2022 2022 Q3
Q4 2020 $359,825 +$507,214 +58% 01 Nov 2020 31 Jan 2021 10-Q 16 Jun 2022 2022 Q3
Q3 2020 $90,050 +$55,423 +38% 01 Aug 2020 31 Oct 2020 10-Q 16 May 2022 2022 Q2
Q1 2020 $533,727 $1,260,063 +$20,871,026 +94% 01 Feb 2020 30 Apr 2020 10-Q 22 Jun 2021 2021 Q3
Q4 2019 $20,337,299 $867,039 +$2,676,382 +76% 01 Nov 2019 31 Jan 2020 10-Q 22 Jun 2021 2021 Q3
Q3 2019 $23,013,681 $145,473 +$293,383 +67% 01 Aug 2019 31 Oct 2019 10-Q 22 Jun 2021 2021 Q3
Q2 2019 $23,307,064 $2,806,302 +$8,424,037 01 May 2019 31 Jul 2019 10-K 04 Nov 2020 2020 FY
Q1 2019 $31,731,101 $22,131,089 -$21,887,031 -8968% 01 Feb 2019 30 Apr 2019 10-Q 22 Jun 2020 2020 Q3
Q4 2018 $9,844,070 $3,543,421 -$3,400,140 -2373% 01 Nov 2018 31 Jan 2019 10-Q 22 Jun 2020 2020 Q3
Q3 2018 $6,443,930 $438,856 -$304,530 -227% 01 Aug 2018 31 Oct 2018 10-Q 22 Jun 2020 2020 Q3
Q2 2018 $6,139,400 $5,617,735 01 May 2018 31 Jul 2018 10-K/A 18 Nov 2019 2020 FY
Q1 2018 $244,058 01 Feb 2018 30 Apr 2018 10-Q 14 Jun 2019 2019 Q3
Q4 2017 $143,281 01 Nov 2017 31 Jan 2018 10-Q 15 Mar 2019 2019 Q2
Q3 2017 $134,326 01 Aug 2017 31 Oct 2017 10-Q 19 Dec 2018 2019 Q1
Q1 2013 $318,253 $20,302 -$9,507 -88% 01 Feb 2013 30 Apr 2013 10-Q 11 Jun 2013 2013 Q3
Q4 2012 $308,746 $51,182 -$48,782 -2033% 01 Nov 2012 31 Jan 2013 10-Q 21 Mar 2013 2013 Q2
Q3 2012 $259,964 $20,112 -$18,412 -1083% 01 Aug 2012 31 Oct 2012 10-Q 14 Dec 2012 2013 Q1
Q2 2012 $241,552 $226,657 -$213,110 -1573% 01 May 2012 31 Jul 2012 10-K 13 Nov 2012 2012 FY
Q1 2012 $28,442 $10,795 -$9,402 -675% 01 Feb 2012 30 Apr 2012 10-Q 11 Jun 2013 2013 Q3
Q4 2011 $19,040 $2,400 +$6,410 +73% 01 Nov 2011 31 Jan 2012 10-Q 21 Mar 2013 2013 Q2
Q3 2011 $25,450 $1,700 -$678 -66% 01 Aug 2011 31 Oct 2011 10-Q 14 Dec 2012 2013 Q1
Q2 2011 $24,772 $13,547 01 May 2011 31 Jul 2011 10-K 13 Nov 2012 2012 FY
Q1 2011 $1,393 01 Feb 2011 30 Apr 2011 10-Q 14 Jun 2012 2012 Q3
Q4 2010 $8,810 01 Nov 2010 31 Jan 2011 10-Q 21 Mar 2012 2012 Q2
Q3 2010 $1,022 01 Aug 2010 31 Oct 2010 10-Q 20 Dec 2011 2012 Q1

THC Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $811,562 -$424,526 -110% 01 Aug 2023 31 Jul 2024 10-K 27 Feb 2026 2024 FY
2023 $387,036 +$1,131,893 +75% 01 Aug 2022 31 Jul 2023 10-K 27 Feb 2026 2024 FY
2022 $1,518,929 +$366,516 +19% 01 Aug 2021 31 Jul 2022 10-K 26 Feb 2024 2023 FY
2021 $1,885,445 -$1,435,570 -319% 01 Aug 2020 31 Jul 2021 10-K 25 Nov 2022 2022 FY
2020 $449,875 +$22,857,189 +98% 01 Feb 2020 31 Jan 2021 10-Q 29 Mar 2021 2021 Q2
2019 $23,307,064 -$17,167,664 -280% 01 Aug 2018 31 Jul 2019 10-K 04 Nov 2020 2020 FY
2018 $6,139,400 01 Aug 2017 31 Jul 2018 10-K/A 18 Nov 2019 2020 FY
2012 $241,552 -$216,780 -875% 01 Aug 2011 31 Jul 2012 10-K 13 Nov 2012 2012 FY
2011 $24,772 +$13,092 +35% 01 Aug 2010 31 Jul 2011 10-K 13 Nov 2012 2012 FY
2010 $37,864 01 Aug 2009 31 Jul 2010 10-K 13 Nov 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.